Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234427 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomics of Antiplatelet Response
A Phase 4 study of Atherosclerosis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT02234427 is a Phase 4 study of Atherosclerosis that has completed, run by Johns Hopkins University. The registered enrollment target is 34 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02234427, a Phase 4 study of Atherosclerosis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease
Conditions Studied
Interventions
- DRUG Aspirin
Study Locations (1)
Maryland
- Johns Hopkins School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234427
The ClinicalTrials.gov registry entry for NCT02234427 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (97% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which Aspirin is the first listed.
NCT02234427 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02234427 about?
NCT02234427 is a clinical study titled "Pharmacogenomics of Antiplatelet Response". This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease
What is the current status of trial NCT02234427?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2014-06. Estimated completion is 2015-05.
What conditions does trial NCT02234427 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT02234427?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT02234427?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02234427 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RECRUITING · Phase 4
-
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.